Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy
Completed · Phase 2
Conditions studied: Drug/Agent Toxicity by Tissue/Organ, Leukemia
In brief
RATIONALE: Silymarin (milk thistle extract) is an herb that may be effective in treating liver disorders caused by cancer therapy. PURPOSE: Randomized phase II trial to study the effectiveness of silymarin in treating patients who have acute lymphoblastic leukemia with chemotherapy-related side effects to the liver.
Key facts
- Study ID
- NCT00055718
- Run by
- Herbert Irving Comprehensive Cancer Center
- People needed
- 50
- Starts
- 2001-11-01
- Expected to finish
- 2010-01-01
- Last updated by the study team
- 2013-12-18
Who can join
Age: 2 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Miami Children's Hospital — Miami, Florida, United States
- Winthrop University Hospital — Mineola, New York, United States
- Mount Sinai School of Medicine — New York, New York, United States
- Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States
- Children's Hospital Medical Center of Akron — Akron, Ohio, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States
- McMaster Children's Hospital at Hamilton Health Sciences — Hamilton, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.